HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Volume 2 (2005), Issue 1 (January)

1. CD8+ T cells from most HIV-1-infected patients, even when challenged with mature dendritic cells, lack functional recall memory to HIV gag but not other viruses.
   Eur J Immunol, 35(1): 159-70. [Abstract] [Full-text]
2. Influence of host genetic variation on susceptibility to HIV type 1 infection.
   J Infect Dis, 191: S68-77. [Abstract] [Full-text]
3. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART.
   J Clin Invest, 115(1): 128-37. [Abstract] [Full-text]
4. The neuropathogenesis of AIDS.
   Nat Rev Immunol, 5(1): 69-81. [Abstract] [Full-text]
5. Harnessing HIV for therapy, basic research and biotechnology.
   Trends Biotechnol, 23(1): 42-7. [Abstract] [Full-text]
6. A PNA-transportan conjugate targeted to the TAR region of the HIV-1 genome exhibits both antiviral and virucidal properties.
   Virology, 331(2): 418-28. [Abstract] [Full-text]
7. Phosphorylation of HIV Nef by cAMP-dependent protein kinase.
   Virology, 331(2): 367-74. [Abstract] [Full-text]
8. Mammalian SCAN domain dimer is a domain-swapped homolog of the HIV capsid C-terminal domain.
   Mol Cell, 17(1): 137-43. [Abstract] [Full-text]
9. Evaluation of the activity of HIV-1 integrase over-expressed in eukaryotic cells.
   Biochem Biophys Res Commun, 327(1): 261-7. [Abstract] [Full-text]
10. IL-7 and IL-15: therapeutic cytokines for immunodeficiency.
    Trends Immunol, 26(1): 56-64. [Abstract] [Full-text]
11. HIV-1 diversity versus HLA class I polymorphism.
    Trends Immunol, 26(1): 41-7. [Abstract] [Full-text]
12. Functionally-inactive and immunogenic Tat, Rev and Nef DNA vaccines derived from sub-Saharan subtype C human immunodeficiency virus type 1 consensus sequences.
    Vaccine, 23(9): 1158-69. [Abstract] [Full-text]
13. The cationic cell-penetrating peptide CPP(TAT) derived from the HIV-1 protein TAT is rapidly transported into living fibroblasts: optical, biophysical, and metabolic evidence.
    Biochemistry, 44(1): 138-48. [Abstract] [Full-text]
14. Solubilization and preformulation studies on PG-300995 (an anti-HIV drug).
    J Pharm Sci, 94(2): 297-303. [Abstract] [Full-text]
15. Immunoarchitecture of lymphoid tissue in HIV-infection during antiretroviral therapy correlates with viral persistence.
    Mod Pathol, 18(1): 127-36. [Abstract] [Full-text]
16. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy.
    J Infect Dis, 191(3): 339-47. [Abstract] [Full-text]
17. Therapeutic response of HIV-1 subtype C in African patients coinfected with either Mycobacterium tuberculosis or human herpesvirus-8.
    J Infect Dis, 191(3): 324-32. [Abstract] [Full-text]
18. Entropy calculation of HIV-1 Env gp120, its receptor CD4, and their complex: an analysis of configurational entropy changes upon complexation.
    Biophys J, 88(1): 15-24. [Abstract] [Full-text]
19. Tuftsin-AZT conjugate: potential macrophage targeting for AIDS therapy.
    J Pept Sci, 11(1): 37-44. [Abstract] [Full-text]
20. Evaluation of an ultrasensitive p24 antigen assay as a potential alternative to human immunodeficiency virus type 1 RNA viral load assay in resource-limited settings.
    J Clin Microbiol, 43(1): 506-8. [Abstract] [Full-text]
21. Evidence for preferential genotyping of a minority human immunodeficiency virus population due to primer-template mismatching during PCR-based amplification.
    J Clin Microbiol, 43(1): 436-8. [Abstract] [Full-text]
22. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis.
    J Clin Microbiol, 43(1): 406-13. [Abstract] [Full-text]
23. HIV-reverse transcriptase inhibition: inclusion of ligand-induced fit by cross-docking studies.
    J Med Chem, 48(1): 200-12. [Abstract] [Full-text]
24. Contrasting effects of natural selection on human and chimpanzee CC chemokine receptor 5.
    Am J Hum Genet, 76(2): 291-301. [Abstract] [Full-text]
25. To reproduce or not: HIV-concordant couples make a critical decision during pregnancy.
    J Midwifery Womens Health, 50(1): 23-30. [Abstract] [Full-text]
26. Synthesis, cellular uptake and HIV-1 Tat-dependent trans-activation inhibition activity of oligonucleotide analogues disulphide-conjugated to cell-penetrating peptides.
    Nucleic Acids Res, 33(1): 27-42. [Abstract] [Full-text]
27. Influenza virus activates human immunodeficiency virus type-1 gene expression in human CD4-expressing T cells through an NF-kappaB-dependent pathway.
    Clin Immunol, 114(2): 190-8. [Abstract] [Full-text]
28. Pediatric human immunodeficiency virus screening in an African district hospital.
    Clin Diagn Lab Immunol, 12(1): 86-92. [Abstract] [Full-text]
29. Functional solubilization of aggregation-prone HIV envelope proteins by covalent fusion with chaperone modules.
    J Mol Biol, 345(5): 1229-41. [Abstract] [Full-text]
30. Antigen-specific beta-chemokine production and CD8 T-cell noncytotoxic antiviral activity in HIV-2-infected individuals.
    Scand J Immunol, 61(1): 63-71. [Abstract] [Full-text]
31. Treatment comparisons for a partially categorical outcome applied to a biomarker with assay limit.
    Stat Med, 24(2): 211-28. [Abstract] [Full-text]
32. Inhibition of HIV-1 gene expression by retroviral vector-mediated small-guide RNAs that direct specific RNA cleavage by tRNase ZL.
    Nucleic Acids Res, 33(1): 235-43. [Abstract] [Full-text]
33. The HLA-B*5703 allele confers susceptibility to the development of spondylarthropathies in Zambian human immunodeficiency virus-infected patients with slow progression to acquired immunodeficiency syndrome.
    Arthritis Rheum, 52(1): 275-9. [Abstract] [Full-text]
34. Phylogenetic demonstration of two cases of perinatal human immunodeficiency virus type 2 infection diagnosed in adulthood.
    AIDS Res Hum Retroviruses, 20(12): 1373-6. [Abstract] [Full-text]
35. Sequence variability of the HIV type 1 protease gene in thai patients experienced with antiretroviral therapy.
    AIDS Res Hum Retroviruses, 20(12): 1368-72. [Abstract] [Full-text]
36. The molecular epidemiology of HIV type 1 among Vietnamese Australian injecting drug users in Melbourne, Australia.
    AIDS Res Hum Retroviruses, 20(12): 1364-7. [Abstract] [Full-text]
37. HIV-1 CRF09_cpx circulates in the North West Province of Cameroon where CRF02_AG infections predominate and recombinant strains are common.
    AIDS Res Hum Retroviruses, 20(12): 1358-63. [Abstract] [Full-text]
38. Genetic diversity of HIV type 1 in Likasi, southeast of the Democratic Republic of Congo.
    AIDS Res Hum Retroviruses, 20(12): 1352-7. [Abstract] [Full-text]
39. DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime.
    AIDS Res Hum Retroviruses, 20(12): 1335-47. [Abstract] [Full-text]
40. Inhibition of HIV type 1 replication using lentiviral-mediated delivery of mutant tRNA(Lys3)A58U.
    AIDS Res Hum Retroviruses, 20(12): 1324-34. [Abstract] [Full-text]
41. Mutation, fitness, viral diversity, and predictive markers of disease progression in a computational model of HIV type 1 infection.
    AIDS Res Hum Retroviruses, 20(12): 1314-23. [Abstract] [Full-text]
42. Genotypic and phenotypic correlates of the HIV Type 1 env gene evolution in infected children with discordant response to antiretroviral therapy.
    AIDS Res Hum Retroviruses, 20(12): 1306-13. [Abstract] [Full-text]
43. Advanced liver fibrosis in HIV/HCV-coinfected patients on antiretroviral therapy.
    AIDS Res Hum Retroviruses, 20(12): 1293-7. [Abstract] [Full-text]
44. Influence of prior structured treatment interruptions on the length of time without antiretroviral treatment in chronically HIV-infected subjects.
    AIDS Res Hum Retroviruses, 20(12): 1283-8. [Abstract] [Full-text]
45. G-->A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo.
    J Virol, 79(3): 1975-80. [Abstract] [Full-text]
46. Anti-CXCR4 monoclonal antibodies recognizing overlapping epitopes differ significantly in their ability to inhibit entry of human immunodeficiency virus type 1.
    J Virol, 79(3): 1930-3. [Abstract] [Full-text]
47. Evidence for heterogeneous selective pressures in the evolution of the env gene in different human immunodeficiency virus type 1 subtypes.
    J Virol, 79(3): 1836-41. [Abstract] [Full-text]
48. Mutation of the SP1 sequence impairs both multimerization and membrane-binding activities of human immunodeficiency virus type 1 Gag.
    J Virol, 79(3): 1803-12. [Abstract] [Full-text]
49. Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy.
    J Virol, 79(3): 1772-88. [Abstract] [Full-text]
50. Human immunodeficiency virus type 1 vectors with alphavirus envelope glycoproteins produced from stable packaging cells.
    J Virol, 79(3): 1765-71. [Abstract] [Full-text]
51. Semen-specific genetic characteristics of human immunodeficiency virus type 1 env.
    J Virol, 79(3): 1734-42. [Abstract] [Full-text]
52. Contribution of virus-like particles to the immunogenicity of human immunodeficiency virus type 1 Gag-derived vaccines in mice.
    J Virol, 79(3): 1701-12. [Abstract] [Full-text]
53. CCR5, GPR15, and CXCR6 are major coreceptors of human immunodeficiency virus type 2 variants isolated from individuals with and without plasma viremia.
    J Virol, 79(3): 1686-700. [Abstract] [Full-text]
54. Genetic recombination of human immunodeficiency virus type 1 in one round of viral replication: effects of genetic distance, target cells, accessory genes, and lack of high negative interference in crossover events.
    J Virol, 79(3): 1666-77. [Abstract] [Full-text]
55. Rodent cells support key functions of the human immunodeficiency virus type 1 pathogenicity factor Nef.
    J Virol, 79(3): 1655-65. [Abstract] [Full-text]
56. Involvement of clathrin-mediated endocytosis in human immunodeficiency virus type 1 entry.
    J Virol, 79(3): 1581-94. [Abstract] [Full-text]
57. Elimination of retroviral infectivity by N-ethylmaleimide with preservation of functional envelope glycoproteins.
    J Virol, 79(3): 1533-42. [Abstract] [Full-text]
58. Preferential use of CXCR4 by R5X4 human immunodeficiency virus type 1 isolates for infection of primary lymphocytes.
    J Virol, 79(3): 1480-6. [Abstract] [Full-text]
59. Virus particle core defects caused by mutations in the human immunodeficiency virus capsid N-terminal domain.
    J Virol, 79(3): 1470-9. [Abstract] [Full-text]
60. Betulinic acid derivatives as HIV-1 antivirals.
    Trends Mol Med, 11(1): 31-6. [Abstract] [Full-text]
61. Lethal mutagenesis of HIV.
    Virus Res, 107(2): 215-28. [Abstract] [Full-text]
62. A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction.
    Curr Biol, 15(1): 73-8. [Abstract] [Full-text]
63. Intestinal parasitic infections and eosinophilia in an human immunedeficiency virus positive population in Honduras.
    Mem Inst Oswaldo Cruz, 99(7): 773-8. [Abstract] [Full-text]
64. Cyclic sulfamide HIV-1 protease inhibitors, with sidechains spanning from P2/P2' to P1/P1'.
    Bioorg Med Chem, 13(3): 755-64. [Abstract] [Full-text]
65. The disease profile of poverty: morbidity and mortality in northern Uganda in the context of war, population displacement and HIV/AIDS.
    Trans R Soc Trop Med Hyg, 99(3): 226-33. [Abstract] [Full-text]
66. HIV-based vectors and angiogenesis following rabbit hindlimb ischemia.
    J Surg Res, 123(1): 55-66. [Abstract] [Full-text]
67. Application of case-crossover and case-time-control study designs in analyses of time-varying predictors of T-cell homeostasis failure.
    Ann Epidemiol, 15(2): 137-44. [Abstract] [Full-text]
68. AIDS and "shared sovereignty" in Tanzania from 1987 to 2000: a case study.
    Soc Sci Med, 60(7): 1613-24. [Abstract] [Full-text]
69. Effect of Plasmodium falciparum malaria on concentration of HIV-1-RNA in the blood of adults in rural Malawi: a prospective cohort study.
    Lancet, 365(9455): 233-40. [Abstract] [Full-text]
70. HIV-1 genotype resistance pattern and evolution in patients failing nelfinavir-containing regimens.
    J Clin Lab Anal, 19(1): 26-9. [Abstract] [Full-text]
71. Weekly docetaxel is safe and effective in the treatment of advanced-stage acquired immunodeficiency syndrome-related Kaposi sarcoma.
    Cancer, 103(2): 417-21. [Abstract] [Full-text]
72. HIV-1 Vpr enhances production of receptor of activated NF-kappaB ligand (RANKL) via potentiation of glucocorticoid receptor activity.
    Arch Virol, 150(1): 67-78. [Abstract] [Full-text]
73. DermaVir: a novel topical vaccine for HIV/AIDS.
    J Invest Dermatol, 124(1): 160-9. [Abstract] [Full-text]
74. Functional variation of HIV-1 Rev Response Element in a longitudinally studied cohort.
    J Med Virol, 75(3): 367-73. [Abstract] [Full-text]
75. Heterogeneous nature of HIV-1 recombinants spreading in Spain.
    J Med Virol, 75(3): 374-80. [Abstract] [Full-text]
76. Polymorphism and drug-selected mutations in the reverse transcriptase gene of HIV-2 from patients living in southeastern France.
    J Med Virol, 75(3): 381-90. [Abstract] [Full-text]
77. Collaborating with an urban community to develop an HIV and AIDS prevention program for black youth and families.
    Behav Modif, 29(2): 370-416. [Abstract] [Full-text]
78. An intervention to promote the female condom to sexually transmitted disease clinic patients.
    Behav Modif, 29(2): 318-69. [Abstract] [Full-text]
79. Development and implementation of a medication adherence training instrument for persons living with HIV: the MATI.
    Behav Modif, 29(2): 286-317. [Abstract] [Full-text]
80. Prevention for HIV-seropositive persons: successive approximation toward a new identity.
    Behav Modif, 29(2): 227-55. [Abstract] [Full-text]
81. Essential role of p53 phosphorylation by p38 MAPK in apoptosis induction by the HIV-1 envelope.
    J Exp Med, 201(2): 279-89. [Abstract] [Full-text]
82. HIV-1 Vpr inhibits the maturation and activation of macrophages and dendritic cells in vitro.
    Int Immunol, 17(2): 103-16. [Abstract] [Full-text]
83. Role of acetylases and deacetylase inhibitors in IRF-1-mediated HIV-1 long terminal repeat transcription.
    Ann N Y Acad Sci, 1030: 636-43. [Abstract] [Full-text]
84. Analysis of the signal transduction pathway leading to human immunodeficiency virus-1-induced interferon regulatory factor-1 upregulation.
    Ann N Y Acad Sci, 1030: 187-95. [Abstract] [Full-text]
85. A subset of human immunodeficiency virus type 1 long-term non-progressors is characterized by the unique presence of ancestral sequences in the viral population.
    J Gen Virol, 86: 355-64. [Abstract] [Full-text]
86. Enhanced immunogenicity using an alphavirus replicon DNA vaccine against human immunodeficiency virus type 1.
    J Gen Virol, 86: 349-54. [Abstract] [Full-text]
87. Predictive value of anti-cell and anti-human immunodeficiency virus (HIV) humoral responses in HIV-1-exposed seronegative cohorts of European and Asian origin.
    J Gen Virol, 86: 339-48. [Abstract] [Full-text]
88. Helical structure determined by NMR of the HIV-1 (345-392)Gag sequence, surrounding p2: implications for particle assembly and RNA packaging.
    Protein Sci, 14(2): 375-86. [Abstract] [Full-text]
89. The magnitude and breadth of hepatitis C virus-specific CD8+ T cells depend on absolute CD4+ T-cell count in individuals coinfected with HIV-1.
    Blood, 105(3): 1170-8. [Abstract] [Full-text]
90. Nutrition and HIV/AIDS in sub-Saharan Africa: an overview.
    Nutrition, 21(1): 96-9. [Abstract] [Full-text]
91. Induction of gp120-specific protective immune responses by genetic vaccination with linear polyethylenimine-plasmid complex.
    Vaccine, 23(11): 1384-92. [Abstract] [Full-text]
92. Effects of virion surface gp120 density on infection by HIV-1 and viral production by infected cells.
    Virology, 332(1): 418-29. [Abstract] [Full-text]
93. Inter-subunit disulfide bonds in soluble HIV-1 envelope glycoprotein trimers.
    Virology, 332(1): 369-83. [Abstract] [Full-text]
94. Role of HIV-2 envelope in Lv2-mediated restriction.
    Virology, 332(1): 347-58. [Abstract] [Full-text]
95. Human immunodeficiency virus type 1 Tat protein induces an intracellular calcium increase in human monocytes that requires DHP receptors: involvement in TNF-alpha production.
    Virology, 332(1): 316-28. [Abstract] [Full-text]
96. Spleen necrosis virus-based vector delivery of anti-HIV-1 genes potently protects human hematopoietic cells from HIV-1 infection.
    Virology, 332(1): 258-71. [Abstract] [Full-text]
97. Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage.
    Virology, 332(1): 145-56. [Abstract] [Full-text]
98. Decreased perforin and granzyme B expression in senescent HIV-1-specific cytotoxic T lymphocytes.
    Virology, 332(1): 16-9. [Abstract] [Full-text]
99. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors.
    Transfusion, 45(2): 254-64. [Abstract] [Full-text]
100. Progress toward an HIV vaccine.
     Annu Rev Med, 56: 213-23. [Abstract] [Full-text]
101. Characterization of human immunodeficiency virus type 1 from a previously unexplored region of South Africa with a high HIV prevalence.
     AIDS Res Hum Retroviruses, 21(1): 103-9. [Abstract] [Full-text]
102. A modified bootscan algorithm for automated identification of recombinant sequences and recombination breakpoints.
     AIDS Res Hum Retroviruses, 21(1): 98-102. [Abstract] [Full-text]
103. Limited evolution in the HIV type 1 pol region among acute seroconverters in Pune, India.
     AIDS Res Hum Retroviruses, 21(1): 93-7. [Abstract] [Full-text]
104. Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials.
     AIDS Res Hum Retroviruses, 21(1): 68-81. [Abstract] [Full-text]
105. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
     AIDS Res Hum Retroviruses, 21(1): 58-67. [Abstract] [Full-text]
106. Nigerian HIV type 2 subtype A and B from heterotypic HIV type 1 and HIV type 2 or monotypic HIV type 2 infections.
     AIDS Res Hum Retroviruses, 21(1): 17-27. [Abstract] [Full-text]
107. Longitudinal assessment of immune response and viral characteristics in HIV-infected patients with prolonged CD4(+)/viral load discordance.
     AIDS Res Hum Retroviruses, 21(1): 13-6. [Abstract] [Full-text]
108. Predictors of HIV serostatus among HIV discordant couples in Lusaka, Zambia and female antenatal clinic attendants in Kigali, Rwanda.
     AIDS Res Hum Retroviruses, 21(1): 5-12. [Abstract] [Full-text]
109. Accessibility and longevity of Internet citations in a clinical AIDS journal.
     AIDS Patient Care STDS, 19(1): 5-8. [Abstract] [Full-text]
110. Predictors of substance use frequency and reductions in seriousness of use among persons living with HIV.
     Drug Alcohol Depend, 77(2): 129-38. [Abstract] [Full-text]
111. The impact of HIV-protease inhibitors on opportunistic parasites.
     Trends Parasitol, 21(2): 58-63. [Abstract] [Full-text]
112. Domain swapping and retroviral assembly.
     Mol Cell, 17(2): 166-7. [Abstract] [Full-text]
113. New estimation method for highly sensitive quantitation of human immunodeficiency virus type 1 DNA and its application.
     J Virol Methods, 124(1): 157-65. [Abstract] [Full-text]
114. Evaluation of a modified version of Heteroduplex Mobility Assay for rapid screening of HIV-1 isolates in epidemics characterized by mono/dual clade predominance.
     J Virol Methods, 124(1): 123-34. [Abstract] [Full-text]
115. Evaluation of the NucliSens EasyQ assay in HIV-1-infected individuals in South Africa.
     J Virol Methods, 124(1): 105-10. [Abstract] [Full-text]
116. A new cell-based assay for measuring the forward mutation rate of HIV-1.
     J Virol Methods, 124(1): 95-104. [Abstract] [Full-text]
117. Effects of unpaired nucleotides within HIV-1 genomic secondary structures on pausing and strand transfer.
     J Biol Chem, 280(4): 2413-23. [Abstract] [Full-text]
118. Antiviral activity of CYC202 in HIV-1-infected cells.
     J Biol Chem, 280(4): 3029-42. [Abstract] [Full-text]
119. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity.
     Curr Biol, 15(2): 166-70. [Abstract] [Full-text]
120. Cluster analysis and three-dimensional QSAR studies of HIV-1 integrase inhibitors.
     J Mol Graph Model, 23(4): 317-28. [Abstract] [Full-text]
121. Three-dimensional structure of HIV-1 virus-like particles by electron cryotomography.
     J Mol Biol, 346(2): 577-88. [Abstract] [Full-text]
122. Role of information sources and socio-demographic factors on knowledge about AIDS in female adolescents.
     J Coll Physicians Surg Pak, 15(1): 18-21. [Abstract] [Full-text]
123. Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks.
     HIV Med, 6(1): 13-20. [Abstract] [Full-text]
124. Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA.
     HIV Med, 6(1): 7-12. [Abstract] [Full-text]
125. Indinavir/ritonavir-based therapy in HIV-1-infected antiretroviral therapy-naive patients: comparison of 800/100 mg and 400/100 mg twice daily.
     HIV Med, 6(1): 1-6. [Abstract] [Full-text]
126. Constitutive association of cell surface CCR5 and CXCR4 in the presence of CD4.
     J Cell Biochem, 93(4): 753-60. [Abstract] [Full-text]
127. Recombination Analysis Tool (RAT): a program for the high-throughput detection of recombination.
     Bioinformatics, 21(3): 278-81. [Abstract] [Full-text]
128. Longitudinal analysis of B cell repertoire and antibody gene rearrangements during early HIV infection.
     Genes Immun, 6(1): 66-9. [Abstract] [Full-text]
129. Acquired rectal fistula in human immunodeficiency virus-positive children: a causal or casual relationship?
     Pediatr Surg Int, 20(11): 898-901. [Abstract] [Full-text]
130. Additive effects of HIV and chronic methamphetamine use on brain metabolite abnormalities.
     Am J Psychiatry, 162(2): 361-9. [Abstract] [Full-text]
131. Weight related differences in the pharmacokinetics of abacavir in HIV-infected patients.
     Br J Clin Pharmacol, 59(2): 183-8. [Abstract] [Full-text]
132. Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients.
     Br J Clin Pharmacol, 59(2): 174-82. [Abstract] [Full-text]
133. A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study).
     J Antimicrob Chemother, 55(2): 246-51. [Abstract] [Full-text]
134. Detection and partial characterization of simian immunodeficiency virus SIVsm strains from bush meat samples from rural Sierra Leone.
     J Virol, 79(4): 2631-6. [Abstract] [Full-text]
135. Genetic analyses of DNA-binding mutants in the catalytic core domain of human immunodeficiency virus type 1 integrase.
     J Virol, 79(4): 2493-505. [Abstract] [Full-text]
136. Kinetics of human immunodeficiency virus type 1 decay following entry into resting CD4+ T cells.
     J Virol, 79(4): 2199-210. [Abstract] [Full-text]
137. Antibody neutralization escape mediated by point mutations in the intracytoplasmic tail of human immunodeficiency virus type 1 gp41.
     J Virol, 79(4): 2097-107. [Abstract] [Full-text]
138. Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse model.
     J Virol, 79(4): 2087-96. [Abstract] [Full-text]
139. Leucine-specific, functional interactions between human immunodeficiency virus type 1 Nef and adaptor protein complexes.
     J Virol, 79(4): 2066-78. [Abstract] [Full-text]
140. Caffeine inhibits human immunodeficiency virus type 1 transduction of nondividing cells.
     J Virol, 79(4): 2058-65. [Abstract] [Full-text]
141. Interactions between natural killer cells and antibody Fc result in enhanced antibody neutralization of human immunodeficiency virus type 1.
     J Virol, 79(4): 2042-9. [Abstract] [Full-text]
142. Mechanism of action and resistant profile of anti-HIV-1 coumarin derivatives.
     Virology, 332(2): 623-8. [Abstract] [Full-text]
143. Clustered epitopes within the Gag-Pol fusion protein DNA vaccine enhance immune responses and protection against challenge with recombinant vaccinia viruses expressing HIV-1 Gag and Pol antigens.
     Virology, 332(2): 467-79. [Abstract] [Full-text]
144. Detection of HIV-1-specific CTL responses in Clade B infection with Clade C Peptides and not Clade B consensus peptides.
     J Immunol Methods, 296(1): 1-10. [Abstract] [Full-text]
145. Vasculopathy of the large arteries in children infected by the human immune deficiency virus.
     Cardiol Young, 14(6): 671-3. [Abstract] [Full-text]
146. Interactions between human immunodeficiency virus and herpes viruses within the oral mucosa.
     Clin Microbiol Infect, 11(2): 83-5. [Abstract] [Full-text]
147. Uncertainties associated with incidence estimates of HIV/AIDS diagnoses adjusted for reporting delay and risk redistribution.
     Stat Med, 24(3): 453-64. [Abstract] [Full-text]

© 2004-2008 HIV Research Today. All Rights Reserved.